A phase III trial of vinflunine + capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with or resistant to an anthracycline and who are taxane resistant
A phase III trial of vinflunine + capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with or resistant to an anthracycline and who are taxane resistant
Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer
A phase III trial of vinflunine + capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with or resistant to an anthracycline and who are taxane resistant
Statut
Status :
Terminé
Type d'étude
Phase III
Age Min.
18
Ans
Age Max.
85
Ans
Genre
Femme
Aire thérapeutique :
Oncologie
Maladie :
Cancer du sein
Traitement :
Vinflunine (Javlor®)
Phase :
Phase III
Date de début de l'étude :
06 Mai 2009
End date :
18 Septembre 2015
Identifiant de l'essai :
L00070 IN 305 B0
Identifiant EudraCT/CTIS :
2008-004171-21
Identifiant CT.gov :
NCT01095003
Envoyer par email